Evidence map›Paper›PMID 39870442›Full record

ArticleMethods in enzymology2025

En masse evaluation of RNA guides (EMERGe) for ADARs.

Prince J Salvador, Natalie M Dugan, Randall Ouye, Peter A Beal

Abstract read
In one paragraph

Article in Methods in enzymology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Prince J SalvadorDepartment of Chemistry, University of California, Davis, 1 Shields Ave, Davis, CA, United States.
Natalie M DuganDepartment of Chemistry, University of California, Davis, 1 Shields Ave, Davis, CA, United States.
Randall OuyeDepartment of Chemistry, University of California, Davis, 1 Shields Ave, Davis, CA, United States.
Peter A BealDepartment of Chemistry, University of California, Davis, 1 Shields Ave, Davis, CA, United States. Electronic address: pabeal@ucdavis.edu.

Funding

Supplement: Defining and Controlling Protein-RNA interactions in editing and interference pathwaysR35GM141907 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PETER A. BEAL · 2021 to 2026
$3.2M
UC Davis Training Program in Chemical BiologyT32GM136597 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHEILA Sue DAVID, Marie C. Heffern · 2021 to 2026
$1.7M
NIGMS NIH HHS R35 GM141907NIGMS NIH HHS T32 GM136597
6 · The paper itself

Abstract

Adenosine Deaminases Acting on RNA (ADARs) convert adenosine to inosine in duplex RNA, and through the delivery of guide RNAs, can be directed to edit specific adenosine sites. As ADARs are endogenously expressed in humans, their editing capacities hold therapeutic potential and allow us to target disease-relevant sequences in RNA through the rationale design of guide RNAs. However, current design principles are not suitable for difficult-to-edit target sites, posing challenges to unlocking the full therapeutic potential of this approach. This chapter discusses how we circumvent this barrier through an in vitro screening method, En Masse Evaluation of RNA Guides (EMERGe), which enables comprehensive screening of ADAR substrate libraries and facilitates the identification of editing-enabling guide strands for specific adenosines. From library generation and screening to next generation sequencing (NGS) data analysis to verification experiments, we describe how a sequence of interest can be identified through this high-throughput screening method. Furthermore, we discuss downstream applications of selected guide sequences, challenges in maximizing library coverage, and potential to couple the screen with machine learning or deep learning models.

Indexed as

Adenosine DeaminaseRNARNA EditingAdenosineGene LibraryHigh-Throughput Nucleotide SequencingHumansAdenosineAdenosine DeaminaseRNAADARHigh-throughput screeningNext-generation sequencingRNA-editing

Identifiers

PMID39870442
PMCPMC12014283

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.